The first GLP-1R agonist, exenatide, also known as Byetta, shared 55% homology to human GLP-1, and when administered with a dose of 5 μg, it significantly improved hyperglycemia in T2D patients [59]. Here, GLP1R is linked to type 2 diabetes mellitus.